ERα is a potent prognostic and predictive marker of endocrine therapy responses for ERα+/PR+ breast tumors [50], and pioneer studies have shown a potent impact of unliganded ERs on breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.